Scarica l'app Stockscreener
15.76
1.50%
-0.24
Precedente Chiudi:
$16.00
Aprire:
$16.01
Volume 24 ore:
15,808
Relative Volume:
0.51
Capitalizzazione di mercato:
$210.76M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-6.75%
1M Prestazione:
-15.04%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$15.47
$16.15
Intervallo di 1 settimana:
$14.71
$16.91
Portata 52W:
$14.71
$19.40
Onkure Therapeutics Inc Stock (OKUR) Company Profile
Nome
Onkure Therapeutics Inc
Settore
Industria
Telefono
(720) 307-2892
Indirizzo
6707 WINCHESTER CIRCLE, SUITE 400, BOULDER
Confronta OKUR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| OKUR | 16.00 | 210.76M | 0 | 0 | 0 | 0.00 |
| VRTX | 450.63 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 749.04 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.59 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.57 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.97 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Onkure Therapeutics Inc Borsa (OKUR) Ultime notizie
OnKure Therapeutics Faces Post-Merger Hurdles: Integration Challenges and Talent Competition Threaten Growth - MSN
OnKure Therapeutics (OKUR) vs. The Competition Head-To-Head Analysis - Defense World
OnKure Therapeutics' (OKUR) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
OnKure Therapeutics announces accounting firm change - Investing.com India
Form 424B3 OnKure Therapeutics, - StreetInsider.com
Reneo Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
OnKure to Present at the Stifel 2024 Healthcare Conference - GlobeNewswire
OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium - GlobeNewswire
VTv, OnKure Terminate Cellular Drug Licensing Agreement - MarketWatch
vTv Therapeutics ends key license agreement with OnKure - Investing.com
vTv Therapeutics ends key license agreement with OnKure By Investing.com - Investing.com UK
vTv Therapeutics Faces License Agreement Termination - TipRanks
OnKure: Looking To Alter PI3K Inhibitor Targeting In Breast Cancer And Beyond (OKUR) - Seeking Alpha
Q3 Earnings Forecast for OKUR Issued By HC Wainwright - MarketBeat
Analysts Offer Predictions for OKUR Q1 Earnings - Defense World
What is HC Wainwright's Estimate for OKUR Q1 Earnings? - MarketBeat
HC Wainwright Reiterates Buy Rating for OnKure Therapeutics (NASDAQ:OKUR) - MarketBeat
OnKure Therapeutics (OKUR) Stock Rebounds In Extended Session - Stocks Telegraph
OnKure started at outperform by Oppenheimer, OKI-219 potential cited - MSN
OnKure shares initiated with Outperform rating on drug potential - Investing.com India
Recently Listed Cancer Firm OnKure's Innovative Approach to Breast Cancer Treatment Sparks Analyst Enthusiasm - Benzinga
OnKure shares initiated with Outperform rating on drug potential By Investing.com - Investing.com Canada
This Builders FirstSource Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Reneo Pharmaceuticals Completes Merger and Name Change to OnKure Therapeutics, Inc. - MarketBeat
Newley merged OnKure raises $65 million - The Pharma Letter
Boulder’s OnKure goes public with merger; key drug trial underway - Boulder Daily Camera
OnKure and Reneo Pharmaceuticals complete merger - Pharmaceutical Technology
Galapagos investor gets board seat; OnKure completes merger with Reneo - Endpoints News
Reneo Pharmaceuticals stockholders approval merger with OnKure - TipRanks
OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million - StockTitan
Reneo stockholders approve merger with OnKure - MSN
Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure - GlobeNewswire
This Stock Is Crushing Nvidia's Performance This Year: Is It Too Late to Buy? - AOL
Here's Why Everyone's Talking About Summit Therapeutics - AOL
Oppenheimer sees competition risk as Relay Therapeutics stock stumbles on trial results - Investing.com
Reneo Pharmaceuticals Reports Second Quarter 2024 Financial Results - Yahoo Finance
OnKure hires ex-Pfizer research leader as chief scientific officer - BizWest
OnKure Therapeutics - The Pharma Letter
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc.RPHM - PR Newswire
OnKure Announces the Appointment of Rogan Nunn, J.D., as General Counsel and Secretary - GlobeNewswire
Reneo Set to Close After Test Failure - Orange County Business Journal
Public Equity Report: Erasca reboots, Telix plans NASDAQ listing - BioCentury
Wilson Sonsini Advises Reneo Pharmaceuticals on IP Matters Related to OnKure Merger - Wilson Sonsini
Reneo Pharma to merge with OnKure - The Pharma Letter
With first drug trial underway, OnKure inks merger with Reneo Pharma to go public - BizWest
Seven biotech companies climbing their way up in Colorado - Labiotech.eu
HDAC Inhibitor Clinical Trial Pipeline Appears Robust With - GlobeNewswire
Fierce Biotech Fundraising Tracker '23: Carmot spinoff Kimia raises $55M; Lassen fuels for fibro-inflammatory mission - Fierce Biotech
The Week’s 10 Biggest Funding Rounds: Anthropic Generates Another Huge Round, Biotech Has Big Week - Crunchbase News
OnKure Therapeutics Announces $54 Million Series C Financing - GlobeNewswire
2023 Destination Startup® drives investment in intermountain west university innovations - University of Colorado Boulder
Onkure Therapeutics Inc Azioni (OKUR) Dati Finanziari
Non sono disponibili dati finanziari per Onkure Therapeutics Inc (OKUR). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Onkure Therapeutics Inc Azioni (OKUR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Leonard Braden Michael | 10% Owner |
Sep 24 '24 |
Buy |
1.41 |
29,600 |
41,866 |
3,388,649 |
| Leonard Braden Michael | 10% Owner |
Sep 17 '24 |
Buy |
1.36 |
55,300 |
75,108 |
3,358,243 |
| Leonard Braden Michael | 10% Owner |
Sep 18 '24 |
Buy |
1.40 |
806 |
1,128 |
3,359,049 |
| Leonard Braden Michael | 10% Owner |
Sep 16 '24 |
Buy |
1.37 |
172,747 |
236,871 |
3,302,943 |
| Leonard Braden Michael | 10% Owner |
Sep 13 '24 |
Buy |
1.31 |
150,000 |
196,950 |
3,130,196 |
| Leonard Braden Michael | 10% Owner |
Sep 12 '24 |
Buy |
1.40 |
36,176 |
50,523 |
2,980,196 |
| Leonard Braden Michael | 10% Owner |
Aug 13 '24 |
Buy |
1.39 |
171,339 |
238,590 |
2,843,533 |
| Leonard Braden Michael | 10% Owner |
Aug 14 '24 |
Buy |
1.41 |
100,487 |
142,008 |
2,944,020 |
| Leonard Braden Michael | 10% Owner |
May 14 '24 |
Buy |
1.54 |
414,281 |
639,578 |
2,672,194 |
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):